Guggenheim Issues Positive Forecast for Johnson & Johnson (NYSE:JNJ) Stock Price

Johnson & Johnson (NYSE:JNJ) had its price target hoisted by Guggenheim from $240.00 to $244.00 in a research note issued to investors on Tuesday,MarketScreener reports. Guggenheim currently has a buy rating on the stock.

JNJ has been the subject of several other research reports. Argus increased their price target on shares of Johnson & Johnson from $210.00 to $240.00 in a research report on Friday, January 23rd. Leerink Partners increased their price target on shares of Johnson & Johnson from $201.00 to $232.00 and gave the company a “market perform” rating in a research report on Thursday, January 22nd. Wall Street Zen cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Wells Fargo & Company increased their price target on shares of Johnson & Johnson from $230.00 to $240.00 and gave the company an “overweight” rating in a research report on Thursday, January 22nd. Finally, Citigroup increased their price target on shares of Johnson & Johnson from $274.00 to $285.00 and gave the company a “buy” rating in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $237.57.

Johnson & Johnson Price Performance

JNJ stock opened at $238.47 on Tuesday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.77 and a current ratio of 1.03. Johnson & Johnson has a 52 week low of $141.50 and a 52 week high of $251.71. The firm’s fifty day moving average is $240.53 and its 200 day moving average is $214.17. The firm has a market cap of $574.38 billion, a P/E ratio of 21.58, a P/E/G ratio of 2.41 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Saturday, January 31st. The company reported $2.46 EPS for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. The company had revenue of $24.28 billion for the quarter. Research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Insider Activity

In other news, EVP Timothy Schmid sold 1,322 shares of the firm’s stock in a transaction dated Friday, February 20th. The shares were sold at an average price of $245.66, for a total value of $324,762.52. Following the completion of the sale, the executive vice president directly owned 25,447 shares of the company’s stock, valued at approximately $6,251,310.02. This trade represents a 4.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Vanessa Broadhurst sold 6,197 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the sale, the executive vice president directly owned 23,003 shares of the company’s stock, valued at approximately $5,598,700.17. This represents a 21.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 30,142 shares of company stock valued at $7,360,528. Corporate insiders own 0.16% of the company’s stock.

Institutional Investors Weigh In On Johnson & Johnson

Several institutional investors and hedge funds have recently modified their holdings of JNJ. AustralianSuper Pty Ltd lifted its position in Johnson & Johnson by 632.0% during the 3rd quarter. AustralianSuper Pty Ltd now owns 89,183 shares of the company’s stock valued at $16,536,000 after acquiring an additional 77,000 shares during the period. J.W. Cole Advisors Inc. lifted its position in Johnson & Johnson by 2.2% during the 3rd quarter. J.W. Cole Advisors Inc. now owns 130,934 shares of the company’s stock valued at $24,278,000 after acquiring an additional 2,769 shares during the period. Guinness Asset Management LTD lifted its position in Johnson & Johnson by 0.4% during the 3rd quarter. Guinness Asset Management LTD now owns 1,383,195 shares of the company’s stock valued at $251,216,000 after acquiring an additional 5,994 shares during the period. Treasurer of the State of North Carolina lifted its position in Johnson & Johnson by 8.3% during the 2nd quarter. Treasurer of the State of North Carolina now owns 1,234,945 shares of the company’s stock valued at $188,638,000 after acquiring an additional 94,957 shares during the period. Finally, National Pension Service lifted its position in Johnson & Johnson by 3.2% during the 3rd quarter. National Pension Service now owns 4,926,569 shares of the company’s stock valued at $913,484,000 after acquiring an additional 151,707 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Citigroup raised its price target to $285 and kept a “buy” rating, implying roughly 20% upside from recent levels — a notable analyst vote of confidence for JNJ’s outlook. Read More.
• Positive Sentiment: Guggenheim also nudged up its target to $244 and maintained a “buy” rating, adding incremental analyst support for the stock. Read More.
• Positive Sentiment: JNJ received CE‑Mark clearance and launched the next‑gen VARIPULSE Pro PFA catheter in Europe — a commercial milestone that should support MedTech sales growth in international markets. Read More.
• Positive Sentiment: Specialty therapy updates: JNJ secured a permanent US reimbursement code for bladder cancer drug INLEXZO, reported 52‑week efficacy for ICOTYDE in psoriasis, and struck an exclusive Japan distribution deal for SIRTURO (drug‑resistant TB). These moves improve commercial visibility and address previous undervaluation arguments. Read More.
• Neutral Sentiment: Technical / timing note: Dow Jones/Investors.com flagged JNJ as in or near a buy zone — bullish from a trading setup perspective but not a fundamental catalyst. Read More.
• Neutral Sentiment: Analyst consensus remains around “Moderate Buy,” reflecting broad analyst support but not unanimous enthusiasm; watch for further analyst commentary and earnings updates. Read More.
• Neutral Sentiment: Longer‑term comparison pieces (e.g., JNJ vs KO) highlight JNJ’s dividend durability and oncology growth but don’t present immediate price catalysts. Read More.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.